Multiple Sclerosis Therapeutics: Unexpected Outcomes Clouding Undisputed Successes
Neurol 72:1008-1015, Wiendl,H. &Hohlfeld,R., 2009
Association of Innovations in Radiotherapy and Systemic Treatments with Clinical Outcomes in Patients with Melanoma Brain Metastasis From 2007 to 2016
JAMA doi:10.1001/JAMANETWORKOPEN.2020.8204, Brastianos, H.C.,et al, 2020
Antibody-Mediated Encephalitis
NEJM 378:840-851, Dalmau, J.,et al, 2018
Autoimmune Encephalitides: A Broadening Field of Treatable Conditions
Neurologist 22:1-13, Kalman, B., 2017
Encephalitis and antibodies to synaptic and neuronal cell surface proteins
Neurol 77:179-189, Lancaster, E.,et al, 2011
Spinal Muscular Atrophy A Timely Review
Arch Neurol 68:979-984, Kolb, S.J.,et al, 2011
Antiretroviral Prophylaxis: A Defining Moment in HIV Control
Lancet 378:e23-25, Karim, S.S. and Karim, Q.A., 2011
Changes in the Incidence and Predictors of Human Immunodeficiency Virus-Associated Dementia in the Era of Highly Active Antiretroviral Therapy
Ann Neurol 63:213-221, Bhaskaran,K.,et al, 2008
Alemtuzumab vs. Interferon Beta-1a in Early Multiple Sclerosis
NEJM 359:1786-1801,1838, The CAMMS223 Trial Investigators, 2008
Natalizumab Plus Interferon Beta -1a for Relapsing Multiple Sclerosis
NEJM 354:911-923,965, Rudick,R.A.,et al, 2006
Von Recklinghausen's Neurofibromatosis: Neurofibromatosis Type 1
Lancet 361:1552-1554, Reynolds,R.M., et al, 2003
The Genetics of Alzheimer Disease, Current Status and Future Prospects
Arch Neurol 55:294-296, Blacker,D.&Tanzi,R.E., 1998
HIV-Protease Inhibitors
NEJM 338:1281-1292, Flexner,C., 1998
HIV Infection-1
BMJ 314:487-491, 579-5831997., Cohn,J.A., 1997
Ocular Manifestations of AIDS
JAMA 275:142-144, 1491996., Whitcup,S.M., 1996
Trinucleotide Repeat Expansion in Neurological Disease
Ann Neurol 36:814-822, LaSpada,A.R.,et al, 1994